<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03677141</url>
  </required_header>
  <id_info>
    <org_study_id>GO40515</org_study_id>
    <secondary_id>2018-001039-29</secondary_id>
    <nct_id>NCT03677141</nct_id>
  </id_info>
  <brief_title>A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of&#xD;
      mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone&#xD;
      (M-CHOP) and, subsequently, in combination with cyclophosphamide, doxorubicin, and prednisone&#xD;
      (CHP) plus polatuzumab vedotin (CHP-pola) in participants with relapsed or refractory (R/R)&#xD;
      B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse&#xD;
      large B-cell lymphoma (DLBCL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 8, 2019</start_date>
  <completion_date type="Anticipated">June 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 22, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AE)</measure>
    <time_frame>Baseline through approximately 90 days after the last study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Response (CR) Rate at the Time of Primary Response Assessment Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Assessed According to Lugano 2014 Response Criteria</measure>
    <time_frame>Approximately 6-8 weeks after Cycle 6 (cycle = 21 days), or at early treatment discontinuation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of Mosunetuzumab</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration (Cmin) of Mosunetuzumab</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of Mosunetuzumab</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of Mosunetuzumab</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of Mosunetuzumab</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Polatuzumab Vedotin</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Plasma Concentration (Cmin) of Polatuzumab Vedotin</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Polatuzumab Vedotin</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL of Polatuzumab Vedotin</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss of Polatuzumab Vedotin</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Objective Response Rate (ORR), Defined as Complete Response (CR) or Partial Response (PR) at any Time on Study Based on PET-CT and/or CT scan as Assessed According to Lugano 2014 Response Criteria</measure>
    <time_frame>Baseline through 2 years after partial response assessment (PRA) (up to a total of approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From the first occurrence of a response to disease progression, relapse, or death, whichever comes first (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibodies (ADAs) to Mosunetuzumab</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADAs to Polatuzumab Vedotin</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>From randomization to the first occurrence of disease progression, relapse, or death from any cause, whichever occurs first (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS at 1 Year</measure>
    <time_frame>Randomization to 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>From randomization to the first occurrence of disease progression or relapse, initiation of new anti-lymphoma therapy (NALT), or death from any cause, whichever occurs first (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in the European Organization for Research and Treatment of Cancer Quality of Life - Core 30 Questionnaire (EORTC QLQ-C30) Physical Functioning and Fatigue</measure>
    <time_frame>From baseline through follow-up (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale</measure>
    <time_frame>From baseline through follow-up (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>B-cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive M-CHOP up to the phase II recommended dose (RP2D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ib: M-CHP-Pola Dose-Finding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive M-CHP-Pola up to the RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with 1L DLBCL will receive mosunetuzumab at the RP2D in combination with CHOP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: M-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with 1L DLBCL will receive M-CHP-Pola at a dose determined in the dose finding stage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with 1L DLBCL will receive R-CHP-Pola at a dose determined in the dose finding stage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: M-CHOP 1L DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with 1L DLBCL will receive M-CHOP at a dose determined in the dose finding stage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mosunetuzumab</intervention_name>
    <description>Participants will receive intravenous (IV) mosunetuzumab.</description>
    <arm_group_label>Phase II: M-CHOP 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort</arm_group_label>
    <arm_group_label>Phase II: M-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase Ib: M-CHP-Pola Dose-Finding</arm_group_label>
    <arm_group_label>Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polatuzumab Vedotin</intervention_name>
    <description>Participants will receive polatuzumab vedotin via IV.</description>
    <arm_group_label>Phase II: M-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase Ib: M-CHP-Pola Dose-Finding</arm_group_label>
    <arm_group_label>Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituxumab</intervention_name>
    <description>Participants will receive rituxumab via IV.</description>
    <arm_group_label>Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Participants will receive cyclophosphamide via IV.</description>
    <arm_group_label>Phase II: M-CHOP 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort</arm_group_label>
    <arm_group_label>Phase II: M-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase Ib: M-CHP-Pola Dose-Finding</arm_group_label>
    <arm_group_label>Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Participants will receive doxorubicin via IV.</description>
    <arm_group_label>Phase II: M-CHOP 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort</arm_group_label>
    <arm_group_label>Phase II: M-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase Ib: M-CHP-Pola Dose-Finding</arm_group_label>
    <arm_group_label>Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Participants will receive vincristine via IV.</description>
    <arm_group_label>Phase II: M-CHOP 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort</arm_group_label>
    <arm_group_label>Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Participants will receive oral prednisone.</description>
    <arm_group_label>Phase II: M-CHOP 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort</arm_group_label>
    <arm_group_label>Phase II: M-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase Ib: M-CHP-Pola Dose-Finding</arm_group_label>
    <arm_group_label>Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Participants will receive tocilizumab via IV.</description>
    <arm_group_label>Phase II: M-CHOP 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort</arm_group_label>
    <arm_group_label>Phase II: M-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase Ib: M-CHP-Pola Dose-Finding</arm_group_label>
    <arm_group_label>Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Phase Ib and Phase II Portions&#xD;
&#xD;
          -  At least one bi-dimensionally measurable nodal lesion, defined as &gt; 1.5 cm in its&#xD;
             longest dimension, or one bi-dimensionally measurable extranodal lesion, defined as &gt;&#xD;
             1.0 cm in its longest diameter&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status of 0, 1, or 2&#xD;
&#xD;
          -  Adequate hematologic function&#xD;
&#xD;
        Inclusion Criteria for Phase Ib Portion&#xD;
&#xD;
        Participants must also meet the following criteria for study entry into the Phase Ib&#xD;
        portion:&#xD;
&#xD;
          -  Histologically confirmed B-cell NHL according to the World Health Organization (WHO)&#xD;
             2016 classification expected to express the cluster of differentiation-20 (CD20)&#xD;
             antigen&#xD;
&#xD;
          -  Relapsed or refractory (R/R) B-cell NHL after at least one prior systemic lymphoma&#xD;
             therapy&#xD;
&#xD;
          -  Treatment with at least one prior CD20-directed therapy&#xD;
&#xD;
          -  Group B only: no prior treatment with polatuzumab vedotin&#xD;
&#xD;
        Inclusion Criteria for Phase II Portion&#xD;
&#xD;
        Participants must also meet the following criteria for study entry in the Phase II portion:&#xD;
&#xD;
          -  Previously untreated, histologically confirmed DLBCL according to WHO 2016&#xD;
             classification&#xD;
&#xD;
          -  International Prognostic Index (IPI) score of 2-5&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Prior treatment with mosunetuzumab&#xD;
&#xD;
          -  Prior allogenic stem-cell transplant&#xD;
&#xD;
          -  Current Grade &gt;1 peripheral neuropathy&#xD;
&#xD;
          -  Participants with history of confirmed progressive multifocal leukoencephalopathy&#xD;
             (PML)&#xD;
&#xD;
          -  Known or suspected chronic active Epstein Barr virus (CAEBV), hepatitis B, hepatitis C&#xD;
             (HCV), or Human Immunodeficiency Virus (HIV)&#xD;
&#xD;
          -  Prior solid organ transplantation&#xD;
&#xD;
          -  History of autoimmune disease&#xD;
&#xD;
          -  Current or past history of central nervous system (CNS) lymphoma&#xD;
&#xD;
          -  Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or&#xD;
             neurodegenerative disease&#xD;
&#xD;
          -  Significant cardiovascular disease or pulmonary disease&#xD;
&#xD;
          -  Clinically significant history of liver disease&#xD;
&#xD;
          -  Recent major surgery within 4 weeks before the start of C1D1, other than superficial&#xD;
             lymph node biopsies for diagnosis&#xD;
&#xD;
        Exclusion Criteria for Phase Ib Portion&#xD;
&#xD;
        Participants who also meet any of the following criteria will be excluded from study entry&#xD;
        in the Phase Ib portion:&#xD;
&#xD;
          -  Prior treatment with chemotherapy, immunotherapy, and biologic therapy 4 weeks prior&#xD;
             to C1D1&#xD;
&#xD;
          -  Prior treatment with radiotherapy within 2 weeks prior to C1D1&#xD;
&#xD;
          -  Adverse events from prior anti-cancer therapy resolved to ≤Grade 1 (with the exception&#xD;
             of alopecia and anorexia)&#xD;
&#xD;
          -  Prior treatment with &gt;250 mg/m^2 doxorubicin (or equivalent anthracycline dose)&#xD;
&#xD;
        Exclusion Criteria for Phase II Portion&#xD;
&#xD;
        Participants who also meet any of the following criteria will be excluded from study entry&#xD;
        in the Phase II portion:&#xD;
&#xD;
          -  Participants with transformed lymphoma&#xD;
&#xD;
          -  Prior therapy for B-cell NHL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California; Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404-2023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Greeley</city>
        <state>Colorado</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Hospital; Cancer Center</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin, Inc.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Salzburg, LKH; Univ.Klinik f. Innere Medizin III der PMU</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Steyr</name>
      <address>
        <city>Steyr</city>
        <zip>4400</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien, Allgemeines Krankenhaus der Stadt Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch-Krankenhaus</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor; Service d'Oncologie Medicale</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel- Centre de Lutte Contre le Cancer</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif CEDEX</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Gyeongsangnam-do</city>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Centre</name>
      <address>
        <city>Gliwice</city>
        <zip>44-102</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Małopolskie Centrum Medyczne</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka</name>
      <address>
        <city>Slupsk</city>
        <zip>76-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych</name>
      <address>
        <city>Warsaw</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Hematologii; Nowotworów Krwi i Transplantacji Szpiku</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala d´Oncologia Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Seville</city>
        <state>Sevilla</state>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara; Servicio de Hematología</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>280146</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

